about
Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancerRhoA as a mediator of clinically relevant androgen action in prostate cancer cellsNew insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancerCytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancerInflammation in prostate cancer progression and therapeutic targetingHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerA novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growthp21-Activated kinase 4 promotes prostate cancer progression through CREBQuantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progressionCYP17 inhibitors for prostate cancer therapyElevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcomeSerum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese populationMAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancerHigh-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerCXCR4 expression in prostate cancer progenitor cellsDifferential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptorNovel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer CellsActivation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.The current state of preclinical prostate cancer animal models.Investigation of risk factors for prostate cancer patients with bone metastasis based on clinical data.Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacityInduction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosisClinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancerTACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancerNovel targeted therapeutics for metastatic castration-resistant prostate cancer.Therapeutic value of quinazoline-based compounds in prostate cancer.The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing.Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.Recent progress on nutraceutical research in prostate cancer.Identification of a clinically relevant androgen-dependent gene signature in prostate cancerThe role of GATA2 in lethal prostate cancer aggressiveness.Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cellsDrug safety is a barrier to the discovery and development of new androgen receptor antagonists.Cell-to-cell signaling influences the fate of prostate cancer stem cells and their potential to generate more aggressive tumors.Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.
P2860
Q24310439-F58002BD-C4C2-41FF-8A8E-6BFE314AA389Q24618899-9A35AA27-F7D1-45C3-A1F5-3478BA010970Q24619151-0F53077E-FEC1-4D24-A5AC-D83785E7C9D8Q24654354-34200A37-369E-4A59-932B-18761D4C1135Q26773610-11EEBA62-CA69-4F97-886E-D3FAFB030CE7Q26773634-592FF3D2-1675-49DF-8510-4E0138721960Q28116222-45ABB373-EC8E-43B7-8B8F-1D7281992D9FQ28269126-7C8C4A42-D17B-4E2D-8A9E-2E63335D6D3DQ28286300-6B70B584-B574-496B-850E-DA01BBD035B3Q28298818-37317786-770E-4D6B-97AE-437084B98F62Q28477590-B09B29BE-3ACB-4BF9-AE50-633B231972D9Q28478038-461C1A4D-E6CE-40B2-AB47-766B1C076014Q28478930-86335E37-CD8A-490F-9C1D-15DD80C0D132Q28480861-78CE4AEA-F228-4BAE-9131-D61F5DC6C518Q28480904-AA337394-418A-4537-ACDC-1EFE8892B9E5Q28534575-39008E05-5877-4675-90D5-6A369B84F1B7Q28545928-A9ACDB17-6695-4512-ABE5-0D1791D45C44Q30408632-0A82518D-29C2-4623-ACD1-76D088595AC5Q30418797-4F437A84-6ECE-4B09-A719-92DFB29293F6Q30568800-F6B06121-AC32-4578-A635-6AFA9746C3EBQ30853584-36B6AED1-4C22-4FC8-84C3-156E8FD9E162Q33363331-62478C8A-3A98-4860-B617-C91AE79FE2ABQ33437726-815EF62F-AF3D-4079-9B2E-FF5E878AC678Q33574512-F65EB0DE-4D23-4557-907A-72CE31B7515CQ33636318-C0D19FA2-AC21-4734-9D5F-F7ADDA383DF4Q33636574-7D1BD547-AEB3-498B-B0C0-34CCA2375EE7Q33642278-2110FC19-0FAD-4EB5-8846-E412C7057F1EQ33746225-D486B03D-05F6-4858-B586-286E36525F84Q33761920-63E6796D-37FD-4466-B5AE-2A168607FE6EQ33770060-AD9F4F5C-21FF-48FF-8BFF-704B0A3610F9Q33770362-DE2B049F-CD56-4224-A151-1190A7194C01Q33775726-3D85CA54-9599-4242-8C41-AA0CE1566E0BQ33818800-E671FDCA-9E91-46D5-8845-393A1C279CD3Q33821752-197B65B8-CEE0-4DD2-8F0A-285AFD881CADQ33848134-09DCB2B3-EDFF-4F9C-95F7-B20B8D33A566Q33968384-E6C8F3AA-E31E-4756-AD91-8818FD0F098FQ34115708-6A032AC4-3198-4FF0-9F89-94095E0F7535Q34140704-B43FC3A1-D989-4DF8-A638-6DF3DE5D6867Q34157307-0DBE639B-6EA4-46F9-85F8-B453746CDCC1Q34296696-E5A20140-8ADF-4BBC-8353-A5BF6402BC1C
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Mechanisms of androgen-refractory prostate cancer.
@en
Mechanisms of androgen-refractory prostate cancer.
@nl
type
label
Mechanisms of androgen-refractory prostate cancer.
@en
Mechanisms of androgen-refractory prostate cancer.
@nl
prefLabel
Mechanisms of androgen-refractory prostate cancer.
@en
Mechanisms of androgen-refractory prostate cancer.
@nl
P356
P1476
Mechanisms of androgen-refractory prostate cancer.
@en
P2093
Donald J Tindall
Jose D Debes
P304
P356
10.1056/NEJMP048178
P407
P577
2004-10-01T00:00:00Z